This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
UK drugdeveloper Scancell said it has chosen a COVID-19 vaccine candidate, SN14, from more than a dozen potential products to advance to a clinical trial. . SN14 works by targeting the coronavirus’ nucleocapsid and spike proteins to prevent viral replication using the company’s ImmunoBody DNA vaccine technology.
Buoyed by the string of successes in early discovery delivered by this approach, attention inevitably turned to how we might leverage the same insights to improve return on capital in the rest of the long path through drugdevelopment. In practice, this looks much more like a traditional pharmacompany than a biotech.
Constructing larger and more diverse screening libraries was, for a while, the competitive advantage of the largest pharmacompanies. The first is the growing popularity of DNA-encoded libraries (DELs). Two solutions, one physical and one computational have emerged.
Srinivasan has led the development of multiple computational pipelines to process data from different next generation sequencing techniques with applications in oncology, genome editing systems including CRISPR-Cas mediated DNA editing, and ADAR-mediated RNA editing. big pharma or startups/spin off? What pro/cons?
Also, payloads that are permeable payloads and specifically microtubule inhibitors or DNA alkylators or chemo. Rich McCormick: Drugdevelopment can be quite challenging. Rich McCormick: How do you strike a balance between the clinical aspects and the commercial demands in your role as the CEO of a pharmacompany?
Various algorithms, trained on data from enormous databases of phages and bacteria, have been developed to predict phage-host relationships in silico rather than find them experimentally with lab work. Middle and Right) Once a bacteriophage lands on a cell, it injects its DNA through a tube (purple) into the unwilling host.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content